Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

This trial is comparing two different immunotherapy combinations given alongside chemotherapy for people newly diagnosed with advanced or spread (metastatic) non-small cell lung cancer (NSCLC). Researchers want to know which combination is more effective. **You may be eligible if...** - You are between 18 and 75 years old - You have been newly diagnosed with advanced or metastatic NSCLC confirmed by biopsy or lab test - You have not received any prior treatment for this lung cancer - Your cancer cannot be removed by surgery or treated with radiation aimed at a cure - You are generally in good physical condition (ECOG score 0–1) with a life expectancy of at least 3 months **You may NOT be eligible if...** - Your cancer has spread to the brain and is untreated - You have significant uncontrolled fluid around your lungs, heart, or belly - You have an active autoimmune disease - You have active hepatitis B, hepatitis C, or a history of immune deficiency - You have a history of serious lung inflammation (interstitial lung disease or pneumonitis) Talk to your doctor to see if this trial is right for you.